Lupin Rationalizes Japan Operations, Sheds Injectables Business
Lupin sells Japanese injectables business, eight years after it made an acquisition in that segment there. The Indian firm now plans to concentrate on building a hybrid pharma model in the country.
You may also be interested in...
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
Pricing pressure in Japan is expected to weigh significantly on growth even in the generics segment, putting the focus on manufacturing and R&D efficiencies to sustain progress in this market, according to senior Lupin executives.
Lupin continues to make niche buys internationally, this time acquiring the Toyko-based specialty injectables firm, I’rom Pharmaceutical Co, for an undisclosed sum.